Viking Therapeutics, Inc. (VKTX)
NASDAQ: VKTX · Real-Time Price · USD
34.38
+0.21 (0.61%)
At close: Aug 26, 2026, 4:00 PM EDT
34.40
+0.02 (0.06%)
After-hours: Aug 26, 2026, 7:53 PM EDT

Viking Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
50.7148.3949.2837.0216.1210.7
Research & Development
509.32344.96101.6463.8154.2344.98
Operating Expenses
560.02393.34150.92100.8370.3655.68
Operating Income
-560.02-393.34-150.92-100.83-70.36-55.68
Interest Expense
-0.01-0.06-0.09-0.09-0.06-0.02
Interest & Investment Income
25.1533.740.9415.021.590.7
Currency Exchange Gain (Loss)
-----0.01
EBT Excluding Unusual Items
-534.88-359.69-110.08-85.9-68.83-54.99
Gain (Loss) on Sale of Investments
0.080.060.11--0.04-
Pretax Income
-534.8-359.64-109.96-85.9-68.87-54.99
Net Income
-534.8-359.64-109.96-85.9-68.87-54.99
Net Income to Common
-534.8-359.64-109.96-85.9-68.87-54.99
Net Income Growth
------
Shares Outstanding (Basic)
115113109947777
Shares Outstanding (Diluted)
115113109947777
Shares Change
2.64%3.33%15.57%22.79%-0.47%6.34%
EPS (Basic)
-4.67-3.19-1.01-0.91-0.90-0.71
EPS (Diluted)
-4.67-3.19-1.01-0.91-0.90-0.71
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
EBIT
-560.02-393.34-150.92-100.83-70.36-55.68
SEC Filings: 10-K · 10-Q